

New from Gaskell

Gaskell is the imprint of the Royal College of Psychiatrists

Acute Psychosis, Schizophrenia and Comorbid Disorders

Recent topics from *Advances in Psychiatric Treatment* Volume 1

Edited by Alan Lee

This new series brings together popular articles from the Royal College of Psychiatrists' Continuing Professional Development Journal: *Advances in Psychiatric Treatment*. These have been updated to provide systematic, authoritative, and well referenced accounts of key clinical topics relating to modern therapeutic practice. Taken together, the first two volumes of this series cover most of the key challenges which present in day to day general adult psychiatric practice. While aimed at all senior psychiatric trainees, their teachers, and other mental health professionals, the books should be especially useful for trainees preparing for part II of the Royal College of Psychiatrists' membership examinations.

The first volume covers the management of acutely disturbed in-patients, drug and psychological approaches to the treatment of schizophrenia, and the problems of comorbid substance misuse and homelessness. There are chapters on risk and childbirth, psychoses in the elderly, and the special problems of identifying and treating psychiatric disorders in those with learning disabilities. There is also practical advice on assessing fitness to be interviewed by the police, and on preparing medico-legal reports.

September 1998, £15.00, 152pp, Paperback, ISBN 1 901242 16 1

Affective and Non-Psychotic Disorders

Recent Topics from *Advances in Psychiatric Treatment* Volume 2

Edited by Alan Lee

The second volume discusses the evidence-based assessment of deliberate self-harm, and covers the special problems of general psychiatric practice when alcohol misuse and severe personality disorder complicate the picture. Chapters relating to depressive disorders begin by focusing on opportunities for psycho-social intervention, and liaison with primary care. There are comparisons of "old" and "new" antidepressants, and reviews of strategies for preventing relapse and recurrence, and managing resistant depression. The special problems of emergency treatment and depression in older patients are identified.

There are expert overviews of brief dynamic psychotherapy, cognitive approaches to treatment, lithium therapy and modern ECT practice. Many chapters emphasise the importance of the rational integration of biological and psychological treatments. There is helpful advice on the specific problems in managing obsessive-compulsive and eating disorders, in dealing with somatisation, and in providing support and treatment for the victims of severe trauma.

October 1999, £15.00, 160pp, Paperback, ISBN 1 901242 17 X

Gaskell books are available from

Book Sales, Royal College of Psychiatrists, 17 Belgrave Square,
London SW1X 8PG. Telephone +44 (0)171 235 2351 extension
146, fax +44 (0)171 245 1231. Credit card orders can be
taken over the telephone.

See the latest information on College publications on the Internet
at <http://www.rcpsych.ac.uk>





Spot the Edronax difference.



 Highly selective noradrenaline re-uptake inhibitor (NARI)¹

 **Edronax**[®]
reboxetine tablets

Helps restore energy and motivation in tired depressed patients^{2,3}

EDRONAX © ABBREVIATED PRESCRIBING INFORMATION

Presentation: Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Posology and method of administration: Adults** 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. **Elderly and children** Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children and therefore reboxetine cannot be recommended in either of these groups. **Renal/Hepatic Insufficiency** 2 mg b.i.d. which can be increased based on patient

precautions for use: Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO-inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure. **Interactions with other medicaments and other forms of interaction:** Reboxetine should not be co-

that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating, tachycardia, vertigo, urinary hesitancy /retention, impotence. **Overdose:** Monitor

NHS Price: Pack of 60 tablets in blisters £19.80. **Legal Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH, UK. **Marketing Authorisation Number:** PL 0032/0216 **References:** 1. Brunello N et al. *Human Psychopharmacology* 1998;13:S13-S19. 2. Dubini A et al. *J Psychopharmacol* 1997; 11(4):S17-S23. 3. Montgomery SA. *Prescriber* April 1998; 116-119. Further information is available from the Marketing Authorisation Holder: Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton Keynes, MK5 8PH, UK. Telephone: 01908 661101. © Edronax is a registered trademark. Code No.P4008/12/98. Date of preparation: November 1998.